

Friday, November 7, 2025

Unless otherwise indicated, the language of presentation is English.

8 : 30–10 : 00

Room 3 (Hall B7 (2), Tokyo International Forum)

Symposium 10

Update for Treatment Strategies for Small Cell Lung Cancer

Chairs : Makoto Nishio
Cancer Institute Hospital of Japanese Foundation for Cancer Research
Kayoko Tsujino
Hyogo Cancer Center

1. Recent evidence on brain radiotherapy in limited-stage small-cell lung cancer **Japanese**
Masaki Nakamura
National Cancer Center Hospital East
2. Current Status and Future Perspectives of Bispecific Antibodies in Small-Cell Lung Cancer **Japanese**
Masahiro Torasawa
Juntendo University Graduate School of Medicine
3. Thoracic radiotherapy for small-cell lung cancer **Japanese**
Shigeo Takahashi
Kagawa University Hospital
4. Therapeutic Development for Small Cell Lung Cancer
Jacob Sands
Dana-Farber Cancer Institute, USA

10 : 40–11 : 40

Poster venue (Hall E, Tokyo International Forum)

P29 Abstract Poster 29

Translational Research

Chair : Ken Tajima
Juntendo University Graduate School of Medicine

1. Integrated Multi-Omics Profiling Identifies CEBPA as an Aging-Related Prognostic Biomarker in NSCLC
Jiaqi Zhu
Affiliated Hospital of Nantong University, China
2. Self-oxygenating PROTAC Microneedles for Tunable Protein Degradation and Enhanced SCLC Therapy
Meng Hou
Shanghai pulmonary hospital, China
3. Targeting MTA2 Lactylation to Overcome Chemoresistance in Lung Adenocarcinoma
SHENCHENG REN
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
4. Assessing Radiation Pneumonitis Risks Using Fractal Analyses in Stage I/II NSCLC Patients with ILD
Jeongeun Hwang
Department of Medical IT Engineering, College of Software Convergence, Soonchunhyang University, Republic of Korea
5. Radiomics Analysis for ILD Prediction in Stage III NSCLC Patients Treated with Durvalumab
Yuichi Ozawa
Hamamatsu Medical Center, Japan
6. Icariside II induces ferroptosis and apoptosis by activating oxidative stress for NSCLC therapy
Yi-yang Jiang
The First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, China

7. Targeting ALDH16A1 to Promote Ferroptosis in SMARCA4-Deficient Non-Small Cell Lung Cancer

Guoshu Bi

Zhongshan Hospital Fudan University, China

8. DAREONTM-8 : a Phase I trial of first-line obixtamig plus SoC in ES-SCLC

Tatsuya Yoshida

Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan

9. Data-Driven Discovery of KEAP1-NRF2 Pathway in Pemetrexed-Resistant Non-Small Cell Lung Cancer

Bagus Radityo Amien

Department of Respiratory Medicine, Juntendo University, Tokyo, Japan

10. Increased Risk of Cancer After Lung Transplantation

Christian A. Merlo

Department of Transplant Pulmonology, Johns Hopkins School of Medicine Faculty, United States of America

12 : 00–12 : 50

Room 3 (Hall B7 (2), Tokyo International Forum)

Luncheon Seminar 14

Chair : Koichi Goto

National Cancer Center Hospital East

Treatment Strategies for HER2-Mutated Metastatic Non-Small Cell Lung Cancer and management of adverse events for T-DXd

Pasi Antero Jänne

Dana-Farber Cancer Institute, USA

DAIICHI SANKYO COMPANY, LIMITED

12 : 00–12 : 50

Room 4 (Hall B5 (1), Tokyo International Forum)

Luncheon Seminar 15

Chair : Takehito Shukuya

Juntendo University Graduate School of Medicine

Optimizing overall survival in ALK+NSCLC

~Lorlatinib : Update analysis from the CROWN study~

Geoffrey Liu

Princess Margaret Cancer Centre, Canada

Pfizer Japan Inc.

12 : 00–12 : 50

Room 6 (Hall D7, Tokyo International Forum)

Luncheon Seminar 17

Chair : Miyako Satouchi

Hyogo Cancer Center

How Should We Consider Evolving Treatment Options for Stage IV Non-Small Cell Lung Cancer?

Stephanie Saw

National Cancer Centre Singapore, Singapore

Astrazeneca K.K.

13 : 35–14 : 35

Room 10 (G510, Tokyo International Forum)

O45 English Session 1

Driver Mutant Lung Cancer I

Chairs : Tomoya Kawaguchi
Graduate School of Medicine, Osaka Metropolitan University
Pasi A. Jänne
Dana-Farber Cancer Institute, USA

1. **A Phase 2 Study of Osimertinib and S-1 in Treatment resistant EGFR mutant NSCLC (SOS-1 study)**
Johan Chan
National Cancer Centre Singapore, Singapore
2. **COCOON : Preventing severe skin issues in EGFR-mutant NSCLC treated with amivantamab+lazer-
tinib**
Toshiaki Takahashi
Division of Thoracic Oncology, Shizuoka Cancer Center, Japan
3. **Long-term survival & treatment patterns with 1L osimertinib in EGFR-mutated advanced NSCLC in
Japan**
Go Saito
Chiba University, Japan
4. **Long-Term Survival Outcome After 1st-line Osimertinib Monotherapy in Advanced NSCLC : LC-
SCRUM-Asia**
Hiroki Izumi
Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan
5. **Subcutaneous after intravenous amivantamab in advanced NSCLC : Initial results from PALOMA-2**
Hiroaki Akamatsu
Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Hospital, Japan
6. **Feasibility of a rapid genomic screening platform of NSCLC in Asia-Pacific : LC-SCRUM-AP**
Virote Sriuranpong
Medical Oncology Unit, Faculty of Medicine, Chulalongkorn University & the King Chulalongkorn Memorial Hospital, Bangkok, Thailand

14 : 40–15 : 40

Room 10 (G510, Tokyo International Forum)

O46 English Session 2

Translational Research I

Chairs : Shinji Sasada
Fraternity Memorial Hospital
Ross Soo
National University Cancer Institute, Singapore

1. **Gallic Acid : A Promising Anti-NSCLC Compound Targeting EGFR for Apoptosis and Ferroptosis**
Binbin Li
The first school of clinical medicine, Shandong University of Traditional Chinese Medicine, China
2. **Skp2 Suppression Induces Cell Senescence in Malignant Pleural Mesothelioma.**
Adityo Wibowo
Juntendo University Graduate School of Medicine, Japan
3. **UPP1 promotes lung adenocarcinoma through inhibiting ferroptosis**
HUIQIN YANG
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, China
4. **HSF4 promotes Adgarasib/Sotorasib resistance in KRAS-G12C-mutated tumor cell lines**
YanJun Yi
Thoracic Surgery, Zhongshan Hospital Affiliated to Fudan University, China

5. Cryobiopsy-based Tri-modality sampling using an ultrathin bronchoscope for peripheral lung lesions
Hayoung Seong
Department of Internal Medicine, Pusan National University Hospital, Republic of Korea
6. Robotic Bronchoscopic Localization in Surgical Management of Pulmonary Nodules
Mayen Gonzalez
Department of Thoracic Surgery, Johns Hopkins School of Medicine Faculty, United States of America

15 : 10–16 : 40

Room 3 (Hall B7 (2), Tokyo International Forum)

Symposium 11

Current Status of Antibody-Drug Conjugate (ADC) Development in Lung Cancer

Chairs : Hidetoshi Hayashi
Kindai University Faculty of Medicine
Koichi Goto
National Cancer Center Hospital East

1. What's going on with ADC in Small Cell Lung Cancer? **Japanese**
Hiroaki Akamatsu
Wakayama Medical University
2. Current Status of Antibody-Drug Conjugate Development in Driver Gene Mutation-Negative Non-Small Cell Lung Cancer **Japanese**
Kentaro Tanaka
Graduate School of Medical and Dental Sciences, Kagoshima University
3. Emerging T-cell Redirecting Immunotherapies for Lung Cancer : Focus on BiTEs and CAR-T Cell Therapy **Japanese**
Tatsuya Yoshida
National Cancer Center Hospital
4. NSCLC Oncogenic Driver Positive
Pasi A. Jänne
Dana Farber Cancer Institute, USA

15 : 15–16 : 45

Room 1 (Hall C, Tokyo International Forum)

Symposium 7

Frontiers in Perioperative Treatment of Resectable Non-Small Cell Lung Cancer - Optimization of Immune Checkpoint Inhibitors and Future Prospects

Chairs : Kenji Suzuki
Juntendo University Graduate School of Medicine
Kazuhisa Takahashi
Juntendo University Graduate School of Medicine

1. Perioperative Therapy and Resectability in Locally Advanced Lung Cancer **Japanese**
Keiju Aokage
National Cancer Center Hospital East
2. Optimal Timing of Perioperative Immunotherapy in Resectable NSCLC : Neoadjuvant, Adjuvant, or Both? **Japanese**
Yasuhiro Tsutani
Kindai University Faculty of Medicine
3. Perioperative Treatment of Resectable NSCLC : Key Considerations for Medical Oncologists **Japanese**
Satoru Miura
Miura Clinic / Niigata Cancer Center Hospital
4. Timing of Perioperative Treatment Overseas
Heather Wakelee
Stanford University/Stanford Cancer Institute, USA

15 : 45–16 : 45

Room 10 (G510, Tokyo International Forum)

O47 English Session 3

Driver Mutant Lung Cancer and SCLC

Chairs : Satoshi Konno
Faculty of Medicine, Hokkaido University
Ticiana Leal
Emory University School of Medicine, USA

1. Efficacy and safety of taletrectinib for ROS1+NSCLC across pivotal studies and between races/regions

Toshiaki Takahashi
Division of Thoracic Oncology, Shizuoka Cancer Center, Japan

2. SUNRAY-02 : A Phase 3 Study of Olomorasib and Immunotherapy in Stage II-III KRAS G12C-Mutant NSCLC

Masahiro Tsuboi
Department of Thoracic Surgery, National Cancer Center Hospital East, Japan

3. Olomorasib+Chemoimmunotherapy in KRAS G12C-Mutant NSCLC : Results from LOXO-RAS-20001 and SUNRAY-01

Jun Sakakibara-Konishi
Hokkaido University Hospital, Japan

4. Different DLL3 expression between post-EGFR-TKI SCLC transformation and de novo SCLC

Jeng-Sen Tseng
Division of Thoracic Oncology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan / Lung Cancer Comprehensive Care and Research Center, Taichung Veterans General Hospital, Taichung, Taiwan / Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan

5. DAREON[®]-9 : a Phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced SCLC

Hiroshi Kagamu
Department of Respiratory Medicine, Saitama Medical University International Medical Center, Japan

6. Olomorasib+Pembrolizumab in KRAS G12C-Mutant NSCLC : Results from LOXO-RAS-20001 and SUNRAY-01

Tadaaki Yamada
Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Japan

16 : 55–18 : 25

Room 1 (Hall C, Tokyo International Forum)

English Outstanding Session

Chairs : Pasi A. Jänne
Dana-Farber Cancer Institute, USA
Jacob Sands
Dana-Farber Cancer Institute, USA

1. Amivantamab+Lazertinib vs Osimertinib in 1L EGFR-mutant Advanced NSCLC : Final OS from MARIPOSA Study

Hidetoshi Hayashi
Department of Medical Oncology, Kindai University Faculty of Medicine, Japan

2. First-line (1L) Osimertinib (osi) ± Chemotherapy (CTx) in EGFRm Advanced NSCLC : FLAURA2 Final OS

Kunihiko Kobayashi
Department of Respiratory Medicine, Saitama Medical University International Medical Center, Hidaka, Saitama, Japan

3. SAVANNAH : Savolitinib+osimertinib in EGFRm aNSCLC and MET OverExp/Amp following PD on osimertinib

Yoshimasa Shiraishi
Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Japan

4. Zongertinib in patients(pts) with previously treated *HER2*-mutant advanced NSCLC : Beamion LUNG-1
Naoki Inui
Department of Clinical Pharmacology and Therapeutics, Division of Respiratory Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan
5. Tarlatamab versus chemotherapy (Ctx) as 2L treatment for SCLC : Primary Analysis of Ph3 DeLLphi-304
Tatsuya Yoshida
National Cancer Center Hospital, Japan
6. Neoadjuvant nivolumab+chemo vs chemo in resectable NSCLC : 5y final data of JP subgroup, Check-Mate 816
Tetsuya Mitsudomi
Izumi City General Hospital / Department of Innovative Medicine, Faculty of Medicine, Kindai University
7. Surgical Outcomes After Neoadjuvant Osimertinib ± Chemotherapy in Resectable EGFRm NSCLC : NeoADAURA
Masahiro Tsuboi
Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan
8. Atezolizumab plus carboplatin and paclitaxel in patients with advanced or recurrent thymic carcinoma (MARBLE)
Yasushi Goto
Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
9. Durvalumab and chemotherapy in ES-SCLC patients with poor performance status (NEJ045A study)
Ryo Morita
Department of Respiratory Medicine, Akita Kousei Medical Center, Akita, Japan.

17 : 00–17 : 50

Room 6 (Hall D7, Tokyo International Forum)

Evening Seminar 7

Chair : Kiyotaka Yoh
National Cancer Center Hospital East

Development of HER2-Targeting Treatments in NSCLC : The Past and Emerging Therapies

Ross Soo
National University Cancer Institute, Singapore

Nippon Boehringer Ingelheim Co., Ltd. Medicine Division

17 : 45–18 : 35

Room 3 (Hall B7 (2), Tokyo International Forum)

Invited Lecture 6

Chair : Yasuhiko Nishioka
Graduate School of Biomedical Sciences, Tokushima University

Lung screening and biomarkers for early detection and management of lung cancer

David Lam
University of Hong Kong, Hong Kong